Literature DB >> 15476280

Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors.

Min Li1, Hui Yang, Hong Chai, William E Fisher, Xiaoping Wang, F Charles Brunicardi, Qizhi Yao, Changyi Chen.   

Abstract

BACKGROUND: Neuropilins (NRPs) are characterized as coreceptors of vascular endothelial growth factor (VEGF). In the current study, the authors assessed the expression of NRPs, VEGF, and vascular endothelial growth factor receptors (VEGFRs), as well as VEGF-induced cell proliferation, in pancreatic carcinoma cell lines and tissue specimens.
METHODS: Human pancreatic carcinoma cell lines (Panc-1 and MIA PaCa-2), normal human pancreatic ductal epithelial cells (HPDE), and human umbilical vein endothelial cells (HUVECs) were cultured. Human pancreatic adenocarcinoma tissue specimens were also studied. Expression levels of NRPs, VEGFRs, and VEGF were determined by real-time polymerase chain reaction analysis and immunostaining. Cell proliferation was examined using a [3H]thymidine incorporation assay.
RESULTS: Both NRP-1 and NRP-2 were expressed in Panc-1 cells, HPDE cells, and HUVECs but were expressed minimally in MIA PaCa-2 cells. Panc-1 expressed 30 times more NRP-1 mRNA than NRP-2 mRNA. NRP-1 levels in Panc-1 cells were 5.3 times higher than in HPDE cells but were similar to NRP-1 levels in HUVECs. NRP-2 levels in Panc-1 cells were similar to NRP-2 levels in HPDE cells but lower than NRP-2 levels in HUVECs. Expression of all three VEGFRs was observed only in HUVECs. However, VEGF mRNA was detected in all cell types except for HUVECs. NRP-1 immunoreactivity levels were much higher than NRP-2 immunoreactivity levels in Panc-1 and human pancreatic adenocarcinoma tissue specimens, whereas VEGFRs were not detected in either of these two settings. In response to VEGF165, [3H]thymidine incorporation in Panc-1 cells increased significantly (by 61%; P < 0.01). A monoclonal antibody against human NRP-1 significantly blocked VEGF-induced cell proliferation in Panc-1 cells.
CONCLUSIONS: The pancreatic carcinoma cell line Panc-1 and adenocarcinoma tissue specimens expressed high levels of NRP-1 and VEGF, but not VEGFRs, and exogenous VEGF significantly increased NRP-1-mediated, but not VEGFR-mediated, Panc-1 cell proliferation. These data suggested that NRP-1 may be involved in the pathogenesis of pancreatic carcinoma. (c) 2004 American Cancer Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476280     DOI: 10.1002/cncr.20634

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Structure-dependent activation of NR4A2 (Nurr1) by 1,1-bis(3'-indolyl)-1-(aromatic)methane analogs in pancreatic cancer cells.

Authors:  Xi Li; Syng-Ook Lee; Stephen Safe
Journal:  Biochem Pharmacol       Date:  2012-03-03       Impact factor: 5.858

2.  EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin.

Authors:  Sharmila Shankar; Luke Marsh; Rakesh K Srivastava
Journal:  Mol Cell Biochem       Date:  2012-09-13       Impact factor: 3.396

3.  NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.

Authors:  Daniel Grun; Gautam Adhikary; Richard L Eckert
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

4.  NRP-1 interacts with GIPC1 and SYX to activate p38 MAPK signaling and cancer stem cell survival.

Authors:  Daniel Grun; Gautam Adhikary; Richard L Eckert
Journal:  Mol Carcinog       Date:  2018-12-21       Impact factor: 4.784

5.  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

Authors:  Min Li; Uddalak Bharadwaj; Rongxin Zhang; Sheng Zhang; Hong Mu; William E Fisher; F Charles Brunicardi; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

6.  Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.

Authors:  Min Li; Xiaochi Wang; Wei Li; Fei Li; Hui Yang; Hao Wang; F Charles Brunicardi; Changyi Chen; Qizhi Yao; William E Fisher
Journal:  Cancer Sci       Date:  2008-09-22       Impact factor: 6.716

7.  Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells.

Authors:  Takayuki Yoshizaki; Wataru Motomura; Sachie Tanno; Shima Kumei; Yumiko Yoshizaki; Satoshi Tanno; Toshikatsu Okumura
Journal:  J Exp Clin Cancer Res       Date:  2010-03-10

8.  Gene profile identifies zinc transporters differentially expressed in normal human organs and human pancreatic cancer.

Authors:  J Yang; Y Zhang; X Cui; W Yao; X Yu; P Cen; S E Hodges; W E Fisher; F C Brunicardi; C Chen; Q Yao; M Li
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

9.  Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression.

Authors:  Min Li; Yuqing Zhang; Zijuan Liu; Uddalak Bharadwaj; Hao Wang; Xinwen Wang; Sheng Zhang; Juan P Liuzzi; Shou-Mei Chang; Robert J Cousins; William E Fisher; F Charles Brunicardi; Craig D Logsdon; Changyi Chen; Qizhi Yao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-14       Impact factor: 11.205

10.  Thymosin Beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation.

Authors:  Yuqing Zhang; Louis W Feurino; Qihui Zhai; Hao Wang; William E Fisher; Changyi Chen; Qizhi Yao; Min Li
Journal:  Cancer Biol Ther       Date:  2007-12-13       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.